Get the latest tech news
Whoop stands firm against FDA pressure over Blood Pressure insights tool
The company and the FDA clash over its Blood Pressure Insights and whether more stringent approval is required.
In a report from Bloomberg, the publication states the FDA (U.S. Food and Drug Administration) is targeting Whoop for the removal of its Blood Pressure Insights (BPI), a feature the latter isn't willing to budge on. Bloomberg notes a statement from an FDA spokesperson today (Aug 13), which says the agency "has not authorized BPI for any use, including for the measurement or estimation of a user’s blood pressure." More importantly, Whoop adds that its Blood Pressure Insights feature is labeled as a wellness-focused tool, and that it is not intended to diagnose more severe cardiovascular medical issues.
Or read this on Android Central
